Literature DB >> 18475459

Interactions between platelet activating factor and eicosanoids during endotoxic shock in anaesthetized pigs.

T Mózes1, F J Zijlstra, J P Heiligers.   

Abstract

The effects of platelet activating factor (PAF) on eicosanoid release during endotoxic shock was investigated in anaesthetized pigs receiving 5 mug kg(-1) Escherichia coli endotoxin (LPS) into the superior mesenteric artery over a 60 min period, by measuring plasma levels of a variety of mediators. Fifteen of the 31 animals infused with LPS and not treated with BN 52021, a PAF receptor antagonist, died within 30 min after the commencement of LPS infusion (non-survivors), while the other 16 survived the experimental period of 3 h, though in a state of shock (survivors). No alterations were observed in plasma concentrations of eicosanoids in the non-survivors. A significant, though transient, increase in eicosanoid concentrations occurred only in the survivors. Treatment with BN 52021 (4 mg kg-1, i.v.) injected 5 min prior to LPS infusion, failed to exert any effect on the survival rate. However, pretreatment with BN 52021 prevented circulatory collapse in the survivors and reduced the concentration of cyclooxygenase enzyme products, without affecting LTB(4) release. Exogenous administration of PAF (0.01 mug kg(-1)) caused hypotension and increased TXB(2) levels although 6-keto PGF(1alpha) and LTB(4) concentrations were unchanged. The data suggest that prostanoid formation may be secondary to PAF release in circulatory collapse evoked by LPS infusion in survivors, and give further support to the suggestion that PAF prostanoid interaction is important during endotoxic shock. However, their role in early death seems to be negligible, indicating the importance of other mediators.

Entities:  

Year:  1992        PMID: 18475459      PMCID: PMC2365336          DOI: 10.1155/S0962935192000280

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  23 in total

1.  Prostacyclin, high density lipoproteins, and myocardial ischemia.

Authors:  A M Lefer
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

2.  Therapy for overwhelming sepsis--clues for treating disease and not just the symptoms.

Authors:  J J Zimmerman
Journal:  Crit Care Med       Date:  1990-01       Impact factor: 7.598

3.  Involvement of eicosanoids in platelet-activating factor-induced modulation of adenylyl cyclase activity in alveolar macrophages.

Authors:  F D Beusenberg; A van Schaik; J G van Amsterdam; I L Bonta
Journal:  J Lipid Mediat       Date:  1991 May-Jun

4.  Platelet activating factor receptor antagonist improves survival and attenuates eicosanoid release in severe endotoxemia.

Authors:  J R Fletcher; A G DiSimone; M A Earnest
Journal:  Ann Surg       Date:  1990-03       Impact factor: 12.969

5.  Serum levels of tumor necrosis factor determine the fatal or non-fatal course of endotoxic shock.

Authors:  T Mózes; S Ben-Efraim; C J Tak; J P Heiligers; P R Saxena; I L Bonta
Journal:  Immunol Lett       Date:  1991-02       Impact factor: 3.685

6.  Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism.

Authors:  M Sánchez-Crespo; F Alonso; P Iñarrea; V Alvarez; J Egido
Journal:  Immunopharmacology       Date:  1982-04

7.  Platelet activating factor is one of the mediators involved in endotoxic shock in pigs.

Authors:  T Mózes; J P Heiligers; C J Tak; F J Zijlstra; S Ben-Efraim; P R Saxena; I L Bonta
Journal:  J Lipid Mediat       Date:  1991-11

8.  Sequential release of eicosanoids during endotoxin-induced shock in anesthetized pigs.

Authors:  T Mózes; F J Zijlstra; J P Heiligers; P R Saxena; I L Bonta
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  1991-04       Impact factor: 4.006

9.  Sequential release of tumour necrosis factor, platelet activating factor and eicosanoids during endotoxin shock in anaesthetized pigs: protective effects of indomethacin.

Authors:  T Mózes; F J Zijlstra; J P Heiligers; C J Tak; S Ben-Efraim; I L Bonta; P R Saxena
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

Review 10.  Recent advances in our understanding of the biochemical interactions between platelet-activating factor and arachidonic acid.

Authors:  F H Chilton; M Cluzel; M Triggiani
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

View more
  2 in total

Review 1.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

2.  Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.

Authors:  D M Albrecht; K van Ackern; H-J Bender; H Hof; W Kox; N Victor; P Funk; M Kieser; S Köhler; D Krausch; I Marzi; T Menges; H Schmidt
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.